Lunit Presents 'Lunit Scope' Research Abstract at Immuno-Oncology Society Conference

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit announced on the 29th that it will present two solo and joint studies related to the application of Lunit AI biomarker in immune checkpoint inhibitor clinical trials and genomic analysis at the 2022 Society for Immunotherapy of Cancer (SITC 2022), held in Boston, USA, from November 8 to 12.

SITC, established in 1984, is the largest conference in the field of immuno-oncology, with over 4,500 members including specialists, government officials, and pharmaceutical and bio experts from 63 countries worldwide.

Last year, Lunit was the first and only Korean medical AI company to attend SITC and presented three research abstracts. This year, it will present research results applying the AI biomarker ‘Lunit SCOPE’ to new drug clinical trials and specific genomic analyses related to the spatial distribution of tumor-infiltrating lymphocytes. Through this, Lunit plans to support that Lunit SCOPE can be used in a wider range of fields such as various clinical trial sites and genomic analysis.

Seobeom Seok, CEO of Lunit, said, “We are pleased to once again present meaningful research results on the clinical utility of Lunit AI biomarker at this SITC,” and added, “Based on this, our ultimate goal at Lunit is to continue active research to provide personalized treatment to cancer patients in all areas.”

This content was produced with the assistance of AI translation services.